Correspondingly, TCZ is a humanized monoclonal antibody that can suppress the bindling of IL-6 to membrane expressed IL-6 soluble receptors, thus preventing the pro-inflammatory activities of IL-6 or IL-6 receptor signaling (Kremer et al., 2011), which might explain TCZ as an effective medication for RA. Here, IL6 is linked to rheumatoid arthritis.